Repare plans for Phase 3 endometrial cancer study, sidelining ovarian cancer

Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in endometrial cancer and ovarian cancer, respectively …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Real-world data reveals factors associated with long-term weight loss in obesity

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide

September 14, 2024

Sage ‘encouraged’ by initial Zurzuvae sales in postpartum depression, but no word on major depression plans

Doctors ordered 120 prescriptions of Zurzuvae, the new pill for postpartum depression, in the final days of December once the drug became available, its manufacturer

February 15, 2024

Denmark’s HTA evolution – Pharmaceutical Technology

New health technology assessment (HTA) statistics produced by Denmark’s Medicine Council (Medicinrådet) for 2024 have prompted GlobalData to take the opportunity to assess evolving HTA

December 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.